Display options
Cite
Malik N, Weintraub WS. The Cardiovascular Risk of Proton Pump Inhibitors and the Dangers of Polypharmacy. Mayo Clin Proc. 2021;96(10):2511-2513doi: 10.1016/j.mayocp.2021.08.017.
Malik, N., & Weintraub, W. S. (2021). The Cardiovascular Risk of Proton Pump Inhibitors and the Dangers of Polypharmacy. Mayo Clinic proceedings, 96(10), 2511-2513. https://doi.org/10.1016/j.mayocp.2021.08.017
Malik, Nitin, and Weintraub, William S. "The Cardiovascular Risk of Proton Pump Inhibitors and the Dangers of Polypharmacy." Mayo Clinic proceedings vol. 96,10 (2021): 2511-2513. doi: https://doi.org/10.1016/j.mayocp.2021.08.017
Malik N, Weintraub WS. The Cardiovascular Risk of Proton Pump Inhibitors and the Dangers of Polypharmacy. Mayo Clin Proc. 2021 Oct;96(10):2511-2513. doi: 10.1016/j.mayocp.2021.08.017. PMID: 34607632.
Copy Download .nbib Format: NLM
Share it on

Mayo Clin Proc. 2021 Oct;96(10):2511-2513. doi: 10.1016/j.mayocp.2021.08.017.

The Cardiovascular Risk of Proton Pump Inhibitors and the Dangers of Polypharmacy.

Mayo Clinic proceedings

Nitin Malik, William S Weintraub

Affiliations

  1. MedStar Heart and Vascular Institute, MedStar Washington Hospital Center, Washington, DC; Georgetown University, Washington, DC.
  2. MedStar Health Research Institute, Washington, DC; Georgetown University, Washington, DC. Electronic address: [email protected].

PMID: 34607632 DOI: 10.1016/j.mayocp.2021.08.017

[No abstract available.]

Publication Types